Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway

Experimental and Therapeutic Medicine

Volumn 15, Issue 4, 2018, Pages 3650-3658

  Wang, Ji ^a   Wang, Chunying ^a   Bu, Gaofeng ^a  

^a Xuzhou City' Infectious Disease Hospital   (China)

Author keywords

Apoptosis; Curcumin; Liver cancer; Mammalian target of rapamycin; Phosphatidylinositol 3 kinase; Protein kinase B; Stem cells

Indexed keywords

CASPASE 3; CASPASE 9; CURCUMIN; CYTOCHROME C; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL PROLIFERATION; CELL SELECTION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; LIVER CANCER; MTT ASSAY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 85043339859     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2018.5805     Document Type: Article

References (57)

1. Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P and Kerr DJ: Hepatocellular carcinoma. Ann Oncol 12: 161-172, 2001.
2. Sherman M: Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154, 2005.
3. Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
4. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
5. Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, Gao YB, Tang WG, Fan J, et al: A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochem Biophys Res Commun 468: 525-532, 2015.
6. Visvader JE: Cells of origin in cancer. Nature 469: 314-322, 2011.
7. Tork OM, Khaleel EF and Abdelmaqsoud OM: Altered cell to cell communication, autophagy and mitochondrial dysfunction in a model of hepatocellular carcinoma: Potential protective effects of curcumin and stem cell therapy. Asian Pac J Cancer Prev 16: 8271-8279, 2015.
8. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
9. Yu W, Zha W, Ke Z, Min Q, Li C, Sun H and Liu C: Curcumin protects neonatal rat cardiomyocytes against high glucose-induced apoptosis via PI3K/Akt signalling pathway. J Diabetes Res 2016: 4158591, 2016.
10. Seto K, Sakabe T, Itaba N, Azumi J, Oka H, Morimoto M, Umekita Y and Shiota G: A novel small-molecule WNT inhibitor, IC-2, has the potential to suppress liver cancer stem cells. Anticancer Res 37: 3569-3579, 2017.
11. Xiao Y, Lin M, Jiang X, Ye J, Guo T, Shi Y and Bian X: The recent advances on liver cancer stem cells: Biomarkers, separation, and therapy. Anal Cell Pathol (Amst) 2017: 5108653, 2017.
12. β-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget 7: 5754-5768, 2016.
13. Sandur SK, Ichikawa H, Pandey MK, Kunnumakkara AB, Sung B, Sethi G and Aggarwal BB: Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med 43: 568-580, 2007.
14. Suckow BK and Suckow MA: Lifespan extension by the antioxidant curcumin in Drosophila melanogaster. Int J Biomed Sci 2: 402-405, 2006.
15. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A and Patumraj S: Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol 14: 2003-2009, 2008.
16. Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E, Tresoldi I, Izzi V, Bernardini R, Palumbo C, et al: Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. J Biol Regul Homeost Agents 27: 105-119, 2013.
17. Zhang CY, Zhang L, Yu HX, Bao JD and Lu RR: Curcumin inhibits the metastasis of K1 papillary thyroid cancer cells via modulating E-cadherin and matrix metalloproteinase-9 expression. Biotechnol Lett 35: 995-1000, 2013.
18. Sun JH, Luo Q, Liu LL and Song GB: Liver cancer stem cell markers: Progression and therapeutic implications. World J Gastroenterol 22: 3547-3557, 2016.
19. κB translocation. Int Immunopharmacol 44: 174-182, 2017.
20. κB related signaling. Biomed Pharmacother 83: 302-313, 2016.
21. He L, Guo Y, Deng Y, Li C, Zuo C and Peng W: Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: The prevention of curcumin. Xenobiotica 47: 154-163, 2017.
22. Zabihi NA, Pirro M, Johnston TP and Sahebkar A: Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des 23: 969-982, 2017.
23. Ellerkamp V, Bortel N, Schmid E, Kirchner B, Armeanu-Ebinger S and Fuchs J: Photodynamic therapy potentiates the effects of curcumin on pediatric epithelial liver tumor cells. Anticancer Res 36: 3363-3372, 2016.
24. Bortel N, Armeanu-Ebinger S, Schmid E, Kirchner B, Frank J, Kocher A, Schiborr C, Warmann S, Fuchs J and Ellerkamp V: Effects of curcumin in pediatric epithelial liver tumors: Inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways. Oncotarget 6: 40680-40691, 2015.
25. α-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells. Mol Med Rep 10: 2505-2510, 2014.
26. Chiablaem K, Lirdprapamongkol K, Keeratichamroen S, Surarit R and Svasti J: Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition. Anticancer Res 34: 1857-1864, 2014.
27. Xu MX, Zhao L, Deng C, Yang L, Wang Y, Guo T, Li L, Lin J and Zhang L: Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the wnt signaling pathway. Int J Oncol 43: 1951-1959, 2013.
28. Dai XZ, Yin HT, Sun LF, Hu X, Zhou C, Zhou Y, Zhang W, Huang XE and Li XC: Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev 14: 3855-3859, 2013.
29. Kim HJ, Park SY, Park OJ and Kim YM: Curcumin suppresses migration and proliferation of Hep3B hepatocarcinoma cells through inhibition of the Wnt signaling pathway. Mol Med Rep 8: 282-286, 2013.
30. Sa G and Das T: Anti cancer effects of curcumin: Cycle of life and death. Cell Div 3: 14, 2008.
31. Yang CL, Liu YY, Ma YG, Xue YX, Liu DG, Ren Y, Liu XB, Li Y and Li Z: Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One 7: e37960, 2012.
32. Sinha D, Biswas J, Sung B, Aggarwal BB and Bishayee A: Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets 13: 1799-1819, 2012.
33. Bhandarkar SS and Arbiser JL: Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol 595: 185-195, 2007.
34. Dandawate PR, Subramaniam D, Jensen RA and Anant S: Targeting cancer stem cells and signaling pathways by phyto-chemicals: Novel approach for breast cancer therapy. Semin Cancer Biol 40-41: 192-208, 2016.
35. Subramaniam D, Kaushik G, Dandawate P and Anant S: Targeting cancer stem cells for chemoprevention of pancreatic cancer. Curr Med Chem: Jan 26, 2017 (Epub ahead of print).
36. Gersey ZC, Rodriguez GA, Barbarite E, Sanchez A, Walters WM, Ohaeto KC, Komotar RJ and Graham RM: Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer 17: 99, 2017.
37. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900, 2001.
38. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
39. Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23: 363-398, 2003.
40. Ravindran J, Prasad S and Aggarwal BB: Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? AAPS J 11: 495-510, 2009.
41. Bagci EZ, Vodovotz Y, Billiar TR, Ermentrout GB and Bahar I: Bistability in apoptosis: Roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J 90: 1546-1559, 2006.
42. Eissing T, Waldherr S, Allgöwer F, Scheurich P and Bullinger E: Response to bistability in apoptosis: Roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J 92: 3332-3334, 2007.
43. Estaquier J, Vallette F, Vayssiere JL and Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med Biol 942: 157-183, 2012.
44. Wurstle ML, Laussmann MA and Rehm M: The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res 318: 1213-1220, 2012.
45. Zhang Y, Kong Y, Liu S, Zeng L, Wan L and Zhang Z: Curcumin induces apoptosis in human leukemic cell lines through an IFIT2-dependent pathway. Cancer Biol Ther 18: 43-50, 2017.
46. Wang C, Zhang X, Teng Z, Zhang T and Li Y: Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice. Eur J Pharmacol 740: 312-320, 2014.
47. Xu X, Qin J and Liu W: Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/Akt signaling pathway. Gene 546: 226-232, 2014.
48. β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem 61: 11817-11824, 2013.
49. Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H and Chen QY: Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol Ther Oncolytics 3: 16018, 2016.
50. Lopes-Rodrigues V, Oliveira A, Correia-da-Silva M, Pinto M, Lima RT, Sousa E and Vasconcelos MH: A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells. Bioorg Med Chem 25: 581-596, 2017.
51. κB survival-signaling pathway. Onco Targets Ther 9: 7373-7384, 2016.
52. Cianciulli A, Calvello R, Porro C, Trotta T, Salvatore R and Panaro MA: PI3k/Akt signalling pathway plays a crucial role in the anti-inflammatory effects of curcumin in LPS-activated microglia. Int Immunopharmacol 36: 282-290, 2016.
53. β-catenin signaling pathway. Med Sci Monit 23: 163-171, 2017.
54. β-catenin signaling. Chem Biol Interact 181: 263-271, 2009.
55. Yang J, Wang C, Zhang Z, Chen X, Jia Y, Wang B and Kong T: Curcumin inhibits the survival and metastasis of prostate cancer cells via the Notch-1 signaling pathway. APMIS 125: 134-140, 2017.
56. κB, uPA activator and MMP9. Oncol Lett 12: 4139-4146, 2016.
57. Dai C, Lei L, Li B, Lin Y, Xiao X and Tang S: Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: Modulation of curcumin. Toxicol Mech Methods 27: 165-172, 2017.